OnKure Therapeutics, Inc. financial data

Symbol
OKUR on Nasdaq
Location
6707 Winchester Circle, Suite 400, Boulder, CO
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24K % -4.74%
Debt-to-equity 23.1 %
Return On Equity -175 % -499%
Return On Assets -63.7 % -116%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.4M shares -1.1%
Common Stock, Shares, Outstanding 3.34M shares -90.1%
Entity Public Float 27.7M USD -81.7%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 13.5M shares +4182%
Weighted Average Number of Shares Outstanding, Diluted 13.5M shares +4182%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 50.1M USD +92.4%
General and Administrative Expense 13.4M USD +3.34%
Operating Income (Loss) -63.5M USD -165%
Net Income (Loss) Attributable to Parent -60.3M USD -148%
Earnings Per Share, Basic 57 USD/shares +97.5%
Earnings Per Share, Diluted 57 USD/shares +97.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 83.4M USD +132%
Cash, Cash Equivalents, and Short-term Investments 76.7M USD
Assets, Current 84.6M USD +8.41%
Property, Plant and Equipment, Net 821K USD +914%
Operating Lease, Right-of-Use Asset 581K USD +17.9%
Other Assets, Noncurrent 116K USD -24.2%
Assets 86.1M USD +9.34%
Accounts Payable, Current 2.38M USD +3620%
Employee-related Liabilities, Current 2.1M USD
Accrued Liabilities, Current 4.66M USD +389%
Liabilities, Current 7.6M USD +464%
Operating Lease, Liability, Noncurrent 267K USD -45.7%
Other Liabilities, Noncurrent 40K USD
Liabilities 7.9M USD +328%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -186M USD +19.9%
Stockholders' Equity Attributable to Parent 78.2M USD
Liabilities and Equity 86.1M USD +9.34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14M USD -31.8%
Net Cash Provided by (Used in) Financing Activities -77K USD -870%
Net Cash Provided by (Used in) Investing Activities -18K USD
Common Stock, Shares Authorized 210M shares +5%
Common Stock, Shares, Issued 3.34M shares -90.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.1M USD -32.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 83.4M USD +347%
Deferred Tax Assets, Valuation Allowance 90.9M USD +309%
Deferred Tax Assets, Gross 90.9M USD +309%
Operating Lease, Liability 823K USD 0%
Payments to Acquire Property, Plant, and Equipment 18K USD +100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41M USD +39.2%
Lessee, Operating Lease, Liability, to be Paid 849K USD -0.24%
Property, Plant and Equipment, Gross 2.18M USD
Operating Lease, Liability, Current 556K USD +68%
Lessee, Operating Lease, Liability, to be Paid, Year Two 560K USD +52.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 560K USD +50.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26K USD -7.14%
Lessee, Operating Lease, Liability, to be Paid, Year Three 285K USD -25.2%
Deferred Tax Assets, Operating Loss Carryforwards 54M USD +498%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 34K USD -88.1%
Operating Lease, Payments 140K USD +164%
Additional Paid in Capital 264M USD -14.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 117K USD +1.74%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.26M USD +60.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares